Cancer institute & Hospital，Chinese Academy of Medical Science
Welcome,         Profile    Billing    Logout  
 6 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiao, Zefen
NCT03731442: Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Recruiting
3
300
RoW
Involved field irradiation, Elective field irradiation, Paclitaxel, Platinum, PEG-rhG-CSF
Chinese Academy of Medical Sciences, The First Affiliated Hospital with Nanjing Medical University, Tianjin Medical University Cancer Institute and Hospital, Anyang Tumor Hospital, Fujian Cancer Hospital, Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital
Esophageal Cancer
10/22
10/27
RATIONALE-311, NCT03957590: A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Active, not recruiting
3
370
RoW
Tislelizumab, BGB-A317, Placebo, Paclitaxel, Cisplatin, Radiotherapy
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
06/25
06/26
NCT02279134: Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma

Active, not recruiting
2/3
360
RoW
Adjuvant Chemoradiation, Adjuvant Radiation, Paclitaxel, Cisplatin or Nedaplatin
Zefen Xiao
Esophageal Neoplasms, Esophageal Cancer
12/22
12/24
NCT05460403: Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection

Recruiting
N/A
3591
RoW
Adjuvant Radiotherapy
Chinese Academy of Medical Sciences, Fujian Cancer Hospital
Esophageal Cancer
07/23
08/23
NCT05543057: Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy

Recruiting
N/A
150
RoW
3DCRT
Zefen Xiao
Esophageal Cancer
01/26
01/26

Download Options